Last updated on 01/04/2022

Asthma Australia is pleased that adults with severe asthma in Australia now have more cost-effective access to a specialised medication to ease their condition. 

The triple combination asthma inhaler Trelegy Ellipta 200/62.5/25, which works to reduce swelling and irritation in the small air passages in the lungs and also open the airways, has been listed on the Pharmaceutical Benefits Scheme from April 1. 

Between 4%-8% of people with asthma are diagnosed with severe asthma, and this announcement will come as welcome news for them and their carers. 

The listing on the PBS means those who benefit from Trelegy Ellipta 200 can do so at a considerably reduced cost, courtesy of subsidies from the Australian Government. 

For more details, read the joint media release below from manufacturing company GSK and Asthma Australia.

Click here to read the media release.